inosine-diphosphate and Cerebral-Infarction

inosine-diphosphate has been researched along with Cerebral-Infarction* in 2 studies

Trials

2 trial(s) available for inosine-diphosphate and Cerebral-Infarction

ArticleYear
[Performance evaluation of integrated cytoprotective therapy of different duration in patients with cerebral infarction].
    Eksperimental'naia i klinicheskaia farmakologiia, 2015, Volume: 78, Issue:1

    The paper reviews the preliminary results of a multicenter randomized clinical research. The aim of the study was to determine the optimal duration of different types of energy-correction therapy. 99 case report forms of patients with cerebral infarction were reviewed with their prior envelope randomization into three groups. Patients in the first group (experimental group), consisting of 32 patients, as part of combined therapy received ascorbic acid (5% solution twice a day in a recommended dosage of 20 ml/day for 20 days); the second group (37 patients) received 10 ml of cytoflavin intravenously by drop infusion twice a day for 10 days; the third group received cytoflavin for 20 days (from day 1 to day 10 - 20 ml a day, from day 11 to day 20 - 10 ml a day). The average NIH scale score on admission was 14.9 ± 2.6. Prescription of cytoflavin came with average 1.7 - 1.8 time regression (p < 0.05) of the volumes of cerebral ischemia in the of cases of the 10- and 20-day courses of treatment, while there were no significant morphologic changes in the ascorbic acid group. These results correlated with the best dynamics and outcomes of the neurological and performance status of patients receiving cytoflavin. Despite the lack of significant general differences in the clinical and morphological data of the second and third groups, the patients with underlying grave medical condition in the 20-day cytoflavin group (with NIH score of 14-20 points on admission) tended to have improved neurologic status parameters in comparison with the experimental group and the 10-day cytoflavin group. These results attest to the advantages of personalized antioxidant energy-correction therapy.

    Topics: Aged; Antioxidants; Ascorbic Acid; Cerebral Infarction; Cognition; Drug Administration Schedule; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Precision Medicine; Psychological Tests; Russia; Severity of Illness Index; Succinates; Treatment Outcome

2015
[Effect of early correction of energy and free-radical homeostasis on the clinical-morphological presentation of cerebral infarction].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Volume: 110, Issue:8

    A randomized comparative prospective 35-day clinical-instrumental trial of 30 patients with an ischemic hemispheric stroke hospitalized on the first day of disease was carried out. In addition to basic therapy, 16 patients of the main group were treated with the antioxidant power-normalizing drug cytoflavin used in dosage 20 ml/day intravenous in drops from the 1st to 10th day and 2 tablets twice a day from the 11th to 35th day. Fourteen patients of the comparison group received basic therapy only. Patient's state was assessed at 0-24 h and 5, 11, 21, 35 days of stroke. Assessment of neurological status (the Glasgow Coma Scale, the NIH stroke scale, a short version of MMSE), brain MRI (brain lesion volume), a study of antioxidant stress markers, assessment of functional outcome (the Barthel index and the modified Rankin scale) were conducted. The early active correction of power and free radical homeostasis by cytoflavin improved the dynamics of brain morphological changes and free-radical changes that was correlated with the activation of consciousness and reduction of neurologic deficit that resulted in the decrease of disability.

    Topics: Adult; Aged; Antioxidants; Biomarkers; Cerebral Infarction; Drug Combinations; Energy Metabolism; Female; Flavin Mononucleotide; Free Radicals; Homeostasis; Humans; Inosine Diphosphate; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Oxidative Stress; Succinates; Treatment Outcome

2010